Navigation Links
Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue
Date:1/12/2009

IRVINE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS), the worldwide leader in intravascular temperature management (IVTM(TM)) therapies for critically ill patients, today announced preliminary, unaudited record fourth quarter and year ended December 31, 2008 revenue.

Fourth quarter 2008 revenue improved more than 40 percent to an expected quarterly record of approximately $3.8 million, compared with $2.7 million in the fourth quarter of 2007. Full year 2008 revenue is expected to be approximately $12.4 million, an annual record, compared with $9.1 million for the full year of 2007. Complete fourth quarter and year-end results will be finalized and reported in early March after completion of the annual audit.

In addition to strong revenue, the number of systems and catheters Alsius sold in the United States during the fourth quarter of 2008 also marked a new high. Sales in Europe increased solidly from the previous year, as well.

"The achievement of record revenue in each of the last three quarters, especially in today's tough capital spending environment, is a testament to two factors: quality products addressing a significant need and adept execution," said Bill Worthen, president and CEO of Alsius. "Expanding awareness among healthcare providers of our IVTM solutions is serving to increase U.S. demand. We are seeing temperature management increasingly incorporated into treatment protocols, as is evidenced by New York City's recent requirement that therapeutic cooling must be available to cardiac arrest victims transported in city ambulances. This growing recognition coupled with the hard work of the Alsius team served to deliver record results. In addition, we were able to build our pipeline of leads during the quarter, which further confirms our belief in the opport
'/>"/>

SOURCE Alsius Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007
2. Alsius Corporation Announces Program for Early Exercise of Warrants
3. Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results
4. Alsius Corporation Receives Regulatory Approval in China and Mexico
5. Alsius Corporation Awarded Three-Year Agreement With MedAssets Supply Chain Systems
6. Alsius Corporation Awarded Three-Year Agreement with HealthTrust Purchasing Group
7. Alsius Corporation Awarded Three-Year Agreement With Premier, Inc.
8. Alsius Corporation to Host Third Quarter 2008 Financial Results Conference Call on November 6
9. Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Teen birth rates ... according to new data released today by the ... the teen birth rate dropped at least 15% in 48 ... , There were also dramatic declines among all racial/ethnic groups ... ,     Birth rates declined 40% or more for Hispanic teens ...
(Date:5/23/2013)... May 23, 2013 To better ... DORMA company, is pleased to announce the release ... for its pacesetting space division products. Provided by ... wallcoverings, the new patterns and colors represent a ... Through meetings with a team of Koroseal experts, ...
(Date:5/23/2013)... can cause rapidly progressing, life threatening meningitis and meningococcal ... have not known how it attaches to the human ... attaches to the airway to colonise", People can be ... while some people progress to invasive disease. To ... how the bacterium colonises the airway. Now that the ...
(Date:5/23/2013)... According to a new market report ... Subscriber Data Management (SDM); Telecom Application Server; Service Creation ... – 2018)", published by MarketsandMarkets, the SDP Market is ... CAGR of 9.15% from 2013 to 2018. , Browse:, ... 84 Figures , 189 Pages ...
(Date:5/23/2013)... May 23, 2013 Verndale, an ... the launch of Current Digital, a business dedicated ... and digital marketing needs. Companies now view content ... business necessity. This can often leave agencies placed ... on preselected software platforms that they may not ...
Breaking Medicine News(10 mins):Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:New discovery in fight against deadly meningococcal disease 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 2Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 3
... being punched by electrical pulses could give better delivery ... treatments //including cancer therapy and gene therapy are limited ... cell membranes. Researchers in San Diego, California, have been ... which involves punching tiny holes into cell membranes using ...
... visions of adult stem cells as a less honestly questionable ... ability to sprout different cell types has spawned debate between ... who say it has life-saving potential. The new findings challenge ... directly produce cell types of other tissues and organs.// It ...
... Food and Drug Administration recommended that three popular allergy drugs ... FDA does not have to follow the advice of its ... for making a decision. // ,"Drugs are prescription ... good and harm. Claritin, Allegra and Zyrtec have almost no ...
... Tea derived from the plants Camellia sinensis contains polyphenols ... flavanols, which gives the tea its antioxidant properties. Polyphenols ... oxidative stress. , ... occur naturally in the body and an increased amount ...
... to a new study shows that women with ... 'good' cholesterol when they take oestrogen.// Previous research suggests ... heart disease. Now doctors at Forest University have discovered ... profile responds to HRT. ,An analysis of over ...
... in University of Texas, a novel blood test can detect ... to predict who might get Alzheimer's disease.Researchers at the School ... a similar blood test would work in people, but the ... ruins brain cells and is the cause of Alzheimer's. Some ...
Cached Medicine News:Health News:A question on study of Adult Stem Cell 2Health News:A question on study of Adult Stem Cell 3Health News:Blood test may aid foretell Alzheimer's 2
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... ATLANTA , May 23, 2013  Inhibikase ... treatments, announced today that it will present new ... at an industry conference sponsored by the PML ... Biogen Idec).  JC polyomavirus (JCV) is the causative ... host-directed tyrosine kinase inhibitor in an extended release ...
(Date:5/23/2013)... , May 23, 2013 ... MKT: NSPR), the leader in embolic protection stents, ... (MGuard for Acute ST Elevation Reperfusion) trial demonstrating ... bare metal and drug eluting stents in all-cause ... patients.  Results from the trial were presented at ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Inquire...
Medicine Products: